The present study was conducted to diagnose obstetric anti-phospholipid syndrome (OAPS) in patients with clinical signs suggestive of anti-phospholipid syndrome (APS), but persistently negative for conventional anti-phospholipid antibodies (aPL). Sera from 61 obstetrical seronegative APS (SN-APS) patients were analyzed for anti-cardiolipin antibodies (aCL) using thin-layer chromatography (TLC)-immunostaining, for anti-cardiolipin/vimentin antibodies (aCL/Vim), anti-phosphatidylserine/prothrombin antibodies, IgA anti-β 2 glycoprotein I antibodies (aβ 2 GPI), and IgA aCL antibodies by enzyme-linked immunosorbent assay. Taken together, our findings show that in 50 out of 61 SN-APS (81.9%) at least one aPL/cofactor antibody was detected using the assays under test. Results revealed that 76% of SN-APS patients resulted positive for aCL by TLC-immunostaining, 54% for aCL/Vim, 12% for aPS/PT, 4% for IgA aβ 2 GPI, and 2% for IgA aCL. Thirty-five out of 61 patients were followed up and the tests were repeated on two occasions, at least 12 weeks apart. Twenty-six out of 35 SN-APS (74.3%) were positive at least one non-conventional test; only 2 patients (5.7%) did not confirm the positivity to the second test. These findings suggest that non-conventional tests, mainly aCL/Vim and aCL detected by TLC-immunostaining, seem to be the most sensitive approaches for finding out aPL in patients with obstetric SN-APS. The use of these tests can be useful for accurate and timely diagnosis of patients with obstetrical APS who are negative for conventional laboratory criteria markers.

Truglia, S., Capozzi, A., Mancuso, S., Recalchi, S., Spinelli, F. R., Perricone, C., De Carolis, C., Manganelli, V., Riitano, G., Garofalo, T., Longo, A., De Carolis, S., Alessandri, C., Misasi, R., Valesini, G., Sorice, M., Conti, F., A monocentric cohort of obstetric seronegative anti-phospholipid syndrome, <<FRONTIERS IN IMMUNOLOGY>>, 2018; 9 (JUL): 1678-1678. [doi:10.3389/fimmu.2018.01678] [http://hdl.handle.net/10807/132719]

A monocentric cohort of obstetric seronegative anti-phospholipid syndrome

Capozzi, Antonella;De Carolis, Caterina;De Carolis, Sara;
2018

Abstract

The present study was conducted to diagnose obstetric anti-phospholipid syndrome (OAPS) in patients with clinical signs suggestive of anti-phospholipid syndrome (APS), but persistently negative for conventional anti-phospholipid antibodies (aPL). Sera from 61 obstetrical seronegative APS (SN-APS) patients were analyzed for anti-cardiolipin antibodies (aCL) using thin-layer chromatography (TLC)-immunostaining, for anti-cardiolipin/vimentin antibodies (aCL/Vim), anti-phosphatidylserine/prothrombin antibodies, IgA anti-β 2 glycoprotein I antibodies (aβ 2 GPI), and IgA aCL antibodies by enzyme-linked immunosorbent assay. Taken together, our findings show that in 50 out of 61 SN-APS (81.9%) at least one aPL/cofactor antibody was detected using the assays under test. Results revealed that 76% of SN-APS patients resulted positive for aCL by TLC-immunostaining, 54% for aCL/Vim, 12% for aPS/PT, 4% for IgA aβ 2 GPI, and 2% for IgA aCL. Thirty-five out of 61 patients were followed up and the tests were repeated on two occasions, at least 12 weeks apart. Twenty-six out of 35 SN-APS (74.3%) were positive at least one non-conventional test; only 2 patients (5.7%) did not confirm the positivity to the second test. These findings suggest that non-conventional tests, mainly aCL/Vim and aCL detected by TLC-immunostaining, seem to be the most sensitive approaches for finding out aPL in patients with obstetric SN-APS. The use of these tests can be useful for accurate and timely diagnosis of patients with obstetrical APS who are negative for conventional laboratory criteria markers.
2018
Inglese
Truglia, S., Capozzi, A., Mancuso, S., Recalchi, S., Spinelli, F. R., Perricone, C., De Carolis, C., Manganelli, V., Riitano, G., Garofalo, T., Longo, A., De Carolis, S., Alessandri, C., Misasi, R., Valesini, G., Sorice, M., Conti, F., A monocentric cohort of obstetric seronegative anti-phospholipid syndrome, <<FRONTIERS IN IMMUNOLOGY>>, 2018; 9 (JUL): 1678-1678. [doi:10.3389/fimmu.2018.01678] [http://hdl.handle.net/10807/132719]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/132719
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact